📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
301 analysed today
FollowTelegram
301
Today
149,702
All-time analysed
42,924
Positive
6,662
Negative
91,435
Neutral
8,613
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
SPARC to Host R&D Day on Jan 8, 2026, to Provide Strategic Pipeline Updates
Sun Pharma Advanced Research Company (SPARC) has scheduled an R&D Day for January 8, 2026, at 4:00 PM IST. The company will provide strategic updates on its prioritized programs and the progress of its innovative drug pipeline. As a research-focused entity, these updates are critical for assessing the company's long-term valuation and clinical trial success. A management presentation will be accessible via a dedicated webcast link during the audio conference.
Key Highlights
R&D Day scheduled for January 8, 2026, at 4:00 PM IST via audio conference.
Strategic updates to be provided on prioritized programs and innovative pipeline progress.
Management presentation link to be active on the day of the call for investor access.
Universal dial-in numbers provided: +91 22 6280 1278 and +91 22 7115 8179.
👀 What to Watch
Investors should monitor the January 8 call for specific updates on clinical trial timelines and potential licensing deals. The stock may experience volatility based on the perceived progress of key drug candidates.
SPARC: U.S. Court Grants Summary Judgement for Sezaby PRV
Sun Pharma Advanced Research Company (SPARC) announced that the U.S. District Court granted summary judgment in favor of SPARC regarding the Priority Review Voucher (PRV) associated with Sezaby. The court held that the FDA's withholding of the PRV was contrary to law. The court stated that no drug product containing phenobarbital sodium was 'previously approved' as defined in the statute. There is a 60-day window for appeals against the motion.
Key Highlights
U.S. District Court granted summary judgment in favor of SPARC for Sezaby PRV
The court allowed 60 days to appeal against the motion
Sezaby is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection
Sezaby was approved by the US FDA for the treatment of neonatal seizures
👀 What to Watch
This is a positive development for SPARC. Investors should monitor any potential appeals filed within the 60-day window.
